CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

203 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

NCT01755078

Hemodialysis Hyperphosphatemia Cardiovascular Events

COMPLETED PHASE4

Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease

NCT00806481

Kidney Failure, Chronic Cardiovascular Diseases

COMPLETED PHASE2

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

NCT01427907

Chronic Kidney Disease

COMPLETED PHASE4

Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease

NCT00151918

Kidney Failure, Chronic

COMPLETED PHASE3

Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

NCT01277497

Chronic Kidney Disease

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiovascular disease is the major cause of death and disability in patients with end-stage renal disease on hemodialysis. It has been hypothesized that ingestion of calcium-based phosphate binders results in net positive calcium balance and vascular calcium deposition. Chertow et al. tested the role of ingested calcium in the progression of cardiovascular calcification in the Treat-To-Goal study (Kidney International 62:245, 2002). They reported that patients treated with calcium-based phosphate binders demonstrated progressive cardiovascular calcification, while patients treated with a calcium-free binder, sevelamer, showed stabilization or improvement in calcification scores. However, the protocol did not prohibit intake of supplemental oral calcium in the sevelamer group, which confounded their ability to accurately test the calcium hypothesis. Moreover, due to the cholesterol sequestering activities of sevelamer, the low-density lipoprotein (LDL) cholesterol was lower among sevelamer-treated patients than the calcium treated patients, resulting in a major imbalance in a cardiovascular risk factor. Lowering LDL level reduces progression of CVC and therefore confounds interpretation of the study. Subsequently, it has been reported in the lay press that patients randomized to sevelamer or calcium-based binders in the Dialysis Clinical Outcomes Revisited (DCOR) study have failed to show a difference in mortality or major secondary endpoints (Suki et al., To be presented American Society of Nephrology November 2005). To circumvent these limitations, the CARE-2 study will test the hypothesis that if LDL levels are lowered to a similar level in calcium acetate and sevelamer-treated patients, there will be no difference in the progression of cardiac calcification. CARE-2 will randomize patients with elevated LDL to calcium acetate or sevelamer. Atorvastatin is added to achieve LDL \< 70 mg/dL in both treatment groups. The primary endpoint is change in cardiac calcification scores, determined by electron beam scanning after 1 year. Secondary endpoints include the ability of calcium acetate and sevelamer to control phosphorus and meet NKF-K/DOQI guidelines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Calcinosis Arteriosclerosis Hyperparathyroidism, Secondary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

PhosLo + atorvastatin

Group Type EXPERIMENTAL

calcium acetate

Intervention Type DRUG

667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level

atorvastatin

Intervention Type DRUG

20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests

2

Sevelamer + atorvastatin

Group Type ACTIVE_COMPARATOR

sevelamer

Intervention Type DRUG

1-3 tablets t.i.d, titrated to serum phosphorus level

atorvastatin

Intervention Type DRUG

20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

calcium acetate

667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level

Intervention Type DRUG

sevelamer

1-3 tablets t.i.d, titrated to serum phosphorus level

Intervention Type DRUG

atorvastatin

20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PhosLo Renagel Lipitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eligible subjects will be male or female patients with end-stage renal disease on maintenance hemodialysis for less than 5 years, with elevated LDL cholesterol
* Currently treated with oral phosphate binders
* Coronary artery calcium scores of 30 to 5000 Agatston units measured by electron beam CT scanning
* Written informed consent
* Negative serum pregnancy test if appropriate
* Expect to comply with protocol procedures and schedule

Exclusion Criteria

* Unstable angina pectoris
* Severe congestive heart failure
* Severe obstructive pulmonary disease requiring supplemental oxygen
* Severe liver dysfunction
* Severe malnutrition
* Severe hyperparathyroidism
* Known HIV
* Active malignancy for which the subject is receiving chemotherapy or radiation
* Planned renal transplant within the next year
* Clinical evidence of calciphylaxis or recent history of hypercalcemia
* History of obstructed bowels
* Hypersensitivity to any of the components of the study medication
* History of swallowing disorders
* Weight \> 300 pounds
* Any condition which makes patient participation not in the patient's best interest

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No